FDA Puts Keytruda on Accelerated Approval Track as Combo Lung Cancer Treatment
News
The U.S. Food and Drug Administration has put Merck‘s Keytruda (pembrolizumab) on an accelerated approval track as a combo treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The accelerated track ... Read more